Mainstay Medical Mainstay Medical Announces Date for 2018 Half Year Results
04 September 2018 - 4:00PM
UK Regulatory
TIDMIRSH
Mainstay Medical International plc ("Mainstay" or the "Company",
Euronext Paris: MSTY.PA and Euronext Dublin: MSTY.IE), a medical
device company focused on bringing to market ReActiv8®, an
implantable restorative neurostimulation system to treat disabling
Chronic Low Back Pain, announces that the Company will release its
2018 Half Year results on 21 September 2018 at 07:00 BST (02:00
EDT, 08:00 CEST).
Jason Hannon, Chief Executive Officer, and Matthew Onaitis,
Chief Financial Officer, will host a conference call and Q&A
for analysts and investors at 13:00 BST (08:00 EDT, 14:00 CEST) on
the day. The call will be conducted in English and a replay will be
available for 30 days. Dial-in details for the call are:
Europe: +44 333 300 0804
Ireland: +353 1 431 1252
France: +33 170750711
Germany: +49 6913803430
USA: +1 6319131422
Participant PIN: 87237611#
The results press release will be available on the 'Investors'
section of the Mainstay Medical website at:
www.mainstay-medical.com/investors
- End -
About Mainstay
Mainstay is a medical device company focused on bringing to
market an innovative implantable restorative neurostimulation
system, ReActiv8®, for people with disabling Chronic Low Back Pain
(CLBP). The Company is headquartered in Dublin, Ireland. It has
subsidiaries operating in Ireland, the United States, Australia,
Germany and the Netherlands, and is listed on the regulated market
of Euronext Paris (MSTY.PA) and the ESM of Euronext Dublin
(MSTY.IE).
About Chronic Low Back Pain
One of the recognized root causes of CLBP is impaired control by
the nervous system of the muscles that dynamically stabilize the
spine in the low back, and an unstable spine can lead to back pain.
ReActiv8 is designed to electrically stimulate the nerves
responsible for contracting these muscles and thereby help to
restore muscle control and improve dynamic spine stability,
allowing the body to recover from CLBP.
People with CLBP usually have a greatly reduced quality of life
and score significantly higher on scales for pain, disability,
depression, anxiety and sleep disorders. Their pain and disability
can persist despite the best available medical treatments, and only
a small percentage of cases result from an identified pathological
condition or anatomical defect that may be correctable with spine
surgery. Their ability to work or be productive is seriously
affected by the condition and the resulting days lost from work,
disability benefits and health resource utilization put a
significant burden on individuals, families, communities, industry
and governments.
Further information can be found at www.mainstay-medical.com
CAUTION - in the United States, ReActiv8 is limited by federal
law to investigational use only.
PR and IR Enquiries:Consilium Strategic Communications
(international strategic communications - business and trade
media)Chris Gardner, Jessica Hodgson, Nicholas BrownTel: +44 203
709 5700 / +44 7921 697 654Email:
mainstaymedical@consilium-comms.comorFTI Consulting (for
Ireland):Jonathan NeilanTel: +353 1 765 0886Email:
jonathan.neilan@fticonsulting.comorNewCap (for France)Julie Coulot,
Tristan Roquet MontégonTel: +33 1 44 71 20 40Email:
jcoulot@newcap.frorAndreasBohne.Com/Kötting Consulting (for
Germany)Andreas BohneTel: +49 2102 1485368Email:
abo@andreasbohne.comorWilhelm KöttingTel: +49 69 75913293Email:
wkotting@gmail.comorInvestor Relations:LifeSci Advisors, LLCBrian
RitchieTel: + 1 (212) 915-2578Email:
britchie@lifesciadvisors.comorESM Advisers:DavyFergal Meegan or
Barry MurphyTel: +353 1 679 6363Email: fergal.meegan@davy.ie or
barry.murphy2@davy.ie
View source version on businesswire.com:
https://www.businesswire.com/news/home/20180903005314/en/
This information is provided by Business Wire
(END) Dow Jones Newswires
September 04, 2018 02:00 ET (06:00 GMT)
Mainstay Medical (LSE:0QUD)
Historical Stock Chart
From Apr 2024 to May 2024
Mainstay Medical (LSE:0QUD)
Historical Stock Chart
From May 2023 to May 2024